Preventing relapse in recurrent depression using mindfulness-based cognitive therapy, antidepressant medication or the combination: trial design and protocol of the MOMENT study

Marloes J Huijbers, Jan Spijker, A Rogier T Donders, Digna J F van Schaik, Patricia van Oppen, Henricus G Ruhé, Marc B J Blom, Willem A Nolen, Johan Ormel, Gert Jan van der Wilt, Willem Kuyken, Philip Spinhoven, Anne E M Speckens, Marloes J Huijbers, Jan Spijker, A Rogier T Donders, Digna J F van Schaik, Patricia van Oppen, Henricus G Ruhé, Marc B J Blom, Willem A Nolen, Johan Ormel, Gert Jan van der Wilt, Willem Kuyken, Philip Spinhoven, Anne E M Speckens

Abstract

Background: Depression is a common psychiatric disorder characterized by a high rate of relapse and recurrence. The most commonly used strategy to prevent relapse/recurrence is maintenance treatment with antidepressant medication (mADM). Recently, it has been shown that Mindfulness-Based Cognitive Therapy (MBCT) is at least as effective as mADM in reducing the relapse/recurrence risk. However, it is not yet known whether combination treatment of MBCT and mADM is more effective than either of these treatments alone. Given the fact that most patients have a preference for either mADM or for MBCT, the aim of the present study is to answer the following questions. First, what is the effectiveness of MBCT in addition to mADM? Second, how large is the risk of relapse/recurrence in patients withdrawing from mADM after participating in MBCT, compared to those who continue to use mADM after MBCT?

Methods/design: Two parallel-group, multi-center randomized controlled trials are conducted. Adult patients with a history of depression (3 or more episodes), currently either in full or partial remission and currently treated with mADM (6 months or longer) are recruited. In the first trial, we compare mADM on its own with mADM plus MBCT. In the second trial, we compare MBCT on its own, including tapering of mADM, with mADM plus MBCT. Follow-up assessments are administered at 3-month intervals for 15 months. Primary outcome is relapse/recurrence. Secondary outcomes are time to, duration and severity of relapse/recurrence, quality of life, personality, several process variables, and incremental cost-effectiveness ratio.

Discussion: Taking into account patient preferences, this study will provide information about a) the clinical and cost-effectiveness of mADM only compared with mADM plus MBCT, in patients with a preference for mADM, and b) the clinical and cost-effectiveness of withdrawing from mADM after MBCT, compared with mADM plus MBCT, in patients with a preference for MBCT.

Trial registration: ClinicalTrials.gov: NCT00928980.

Figures

Figure 1
Figure 1
Flow chart of the recruitment and study procedure.

References

    1. Frank E, Prien RF, Jarrett RB, Keller MB, Kupfer DJ, Lavori PW, Rush AJ, Weissman MM. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Remission, recovery, relapse, and recurrence. Arch Gen Psychiatry. 1991;48(9):85–855.
    1. Mueller TI, Leon AC, Keller MB, Solomon DA, Endicott J, Coryell W, Warshaw M, Maser JD. Recurrence after recovery from major depressive disorder during 15 years of observational follow-up. Am J Psychiatry. 1999;156(7):1000–1006.
    1. Solomon DA, Keller MB, Leon AC, Mueller TI, Lavori PW, Shea MT, Coryell W, Warshaw M, Turvey C, Maser JD. et al.Multiple recurrences of major depressive disorder. Am J Psychiatry. 2000;157(2):229–233. doi: 10.1176/appi.ajp.157.2.229.
    1. National Institute for Clinical Excellence. Depression: management of depression in primary and secondary care. London: National Institute for Health and Clinical Excellence; 2004. NICE guidance.
    1. Geddes JR, Carney SM, Davies C, Furukawa TA, Kupfer DJ, Frank E, Goodwin GM. Relapse prevention with antidepressant drug treatment in depressive disorders: a systematic review. Lancet. 2003;361(9358):653–661. doi: 10.1016/S0140-6736(03)12599-8.
    1. Bockting CL, ten Doesschate MC, Spijker J, Spinhoven P, Koeter MW, Schene AH. Continuation and maintenance use of antidepressants in recurrent depression. Psychother Psychosom. 2008;77(1):17–26. doi: 10.1159/000110056.
    1. ten Doesschate MC, Bockting CL, Schene AH. Adherence to continuation and maintenance antidepressant use in recurrent depression. J Affect Disord. 2009;115(1–2):167–170.
    1. Kelly K, Posternak M, Alpert JE. Toward achieving optimal response: understanding and managing antidepressant side effects. Dialogues Clin Neurosci. 2008;10(4):409–418.
    1. van Schaik D, Klijn A, van Hout H, van Marwijk H, Beekman A, de Haan M, van Dyck R. Patients’ preferences in the treatment of depressive disorder in primary care. Gen Hosp Psychiatry. 2004;26:184–189. doi: 10.1016/j.genhosppsych.2003.12.001.
    1. Dobson KS, Hollon SD, Dimidjian S, Schmaling KB, Kohlenberg RJ, Gallop RJ, Rizvi SL, Gollan JK, Dunner DL, Jacobson NS. Randomized trial of behavioral activation, cognitive therapy, and antidepressant medication in the prevention of relapse and recurrence in major depression. J Consult Clin Psychol. 2008;76(3):468–477.
    1. Segal ZV, Williams JMG, Teasdale JD. Mindfulness-based cognitive therapy for depression: a new approach to preventing relapse. New York: Guilford Press; 2002.
    1. Scher CD, Ingram RE, Segal ZV. Cognitive reactivity and vulnerability: Empirical evaluation of construct activation and cognitive diatheses in unipolar depression. Clin Psychol Rev. 2005;25(4):487–510. doi: 10.1016/j.cpr.2005.01.005.
    1. Segal ZV, Gemar M, Williams S. Differential cognitive response to a mood challenge following successful cognitive therapy or pharmacotherapy for unipolar depression. J Abnorm Psychol. 1999;108(1):3–10.
    1. Robinson MS, Alloy LB. Negative cognitive styles and stress-reactive rumination interact to predict depression: A prospective study. Cognitive Therapy and Research. 2003;27(3):275–291. doi: 10.1023/A:1023914416469.
    1. Nolen-Hoeksema S. The role of rumination in depressive disorders and mixed anxiety/depressive symptoms. J Abnorm Psychol. 2000;109(3):504–511.
    1. Kuyken W, Watkins E, Holden E, White K, Taylor RS, Byford S, Evans A, Radford S, Teasdale JD, Dalgleish T. How does mindfulness-based cognitive therapy work? Behav Res Ther. 2010;48(11):1105–1112. doi: 10.1016/j.brat.2010.08.003.
    1. van Aalderen JR, Donders AR, Giommi F, Spinhoven P, Barendregt HP, Speckens AE. The efficacy of mindfulness-based cognitive therapy in recurrent depressed patients with and without a current depressive episode: a randomized controlled trial. Psychol Med. 2012;42(5):989–1001. doi: 10.1017/S0033291711002054.
    1. Neff KD. Self-compassion: An alternative conceptualization of a healthy attitude toward oneself. Self and Identity. 2003;2:85–101. doi: 10.1080/15298860309032.
    1. Teasdale JD, Segal ZV, Williams JM, Ridgeway VA, Soulsby JM, Lau MA. Prevention of relapse/recurrence in major depression by mindfulness-based cognitive therapy. JConsult ClinPsychol. 2000;68(4):615–623.
    1. Ma SH, Teasdale JD. Mindfulness-based cognitive therapy for depression: replication and exploration of differential relapse prevention effects. JConsult ClinPsychol. 2004;72(1):31–40.
    1. Godfrin K, van Heeringen C. The effects of mindfulness-based cognitive therapy on recurrence of depressive episodes, mental health and quality of life: A randomized controlled study. Behav Res Ther. 2010;48(8)
    1. Geschwind N, Peeters F, Huibers M, van Os J, Wichers M. Efficacy of mindfulness-based cognitive therapy in relation to prior history of depression: randomised controlled trial. Br J Psychiatry. 2012, August 9.
    1. Kuyken W, Byford S, Taylor RS, Watkins E, Holden E, White K, Barrett B, Byng R, Evans A, Mullan E. et al.Mindfulness-based cognitive therapy to prevent relapse in recurrent depression. JConsult ClinPsychol. 2008;76(6):966–978.
    1. Segal ZV, Bieling P, Young T, MacQueen G, Cooke R, Martin L, Bloch R, Levitan RD. Antidepressant Monotherapy vs Sequential Pharmacotherapy and Mindfulness-Based Cognitive Therapy, or Placebo, for Relapse Prophylaxis in Recurrent Depression. Arch Gen Psychiatry. 2010;67(12):1256–1264. doi: 10.1001/archgenpsychiatry.2010.168.
    1. Piet J, Hougaard E. The effect of mindfulness-based cognitive therapy for prevention of relapse in recurrent major depressive disorder: a systematic review and meta-analysis. Clin Psychol Rev. 2011;31(6):1032–1040. doi: 10.1016/j.cpr.2011.05.002.
    1. FDA. Draft guidance for industry on non-inferiority clinical trials. Food and Drug Administration. 2010. Available at: .
    1. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4. Washington, DC: American Psychiatric Association; 2000.
    1. First MB, Gibbon M, Spitzer RL, Williams JBW. User Guide for the Structured Clinical Interview for DSM-IV Axis 1 Disorders. Washington, DC: American Psychiatric Association; 1996.
    1. Akkerhuis GW. Vertaling IDS. Utrecht: H.C. Rümke Groep; 1997.
    1. Rush AJ, Trivedi MH, Ibrahim HM, Carmody TJ, Arnow B, Klein DN, Markowitz JC, Ninan PT, Kornstein S, Manber R. et al.The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depression. Biol Psychiatry. 2003;54(5):573–583. doi: 10.1016/S0006-3223(02)01866-8.
    1. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, Hergueta T, Baker R, Dunbar GC. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 2):22–33. quiz 34-57.
    1. Moleman P. Praktische psychofarmacologie. Houten: Prelum; 2009.
    1. Fawcett J, Epstein P, Fiester SJ, Elkin I, Autry JH. Clinical management--imipramine/placebo administration manual. NIMH Treatment of Depression Collaborative Research Program. Psychopharmacol Bull. 1987;23(2):309–324.
    1. Kabat-Zinn J. Full Catastrophe Living: Using the Wisdom of Your Body and Mind to Face Stress. Pain and Illness New York: Delacorte; 1990.
    1. Beck AT, Rush AJ, Shaw BF, Emery G. Cognitive Therapy of Depression. New York: The Guilford Press; 1979.
    1. Crane RS, Kuyken W, Williams JMG, Hastings RP, Cooper L, Fennell MJV. Competence in Teaching Mindfulness-Based Courses: Concepts, Development and Assessment. Mindfulness. 2012;3:76–84. doi: 10.1007/s12671-011-0073-2.
    1. Rosenbaum JF, Fava M, Hoog SL, Ascroft RC, Krebs WB. Selective serotonin reuptake inhibitor discontinuation syndrome: a randomized clinical trial. Biol Psychiatry. 1998;44(2):77–87. doi: 10.1016/S0006-3223(98)00126-7.
    1. Lobbestael J, Leurgans M, Arntz A. Inter-rater reliability of the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID I) and Axis II Disorders (SCID II) Clin Psychol Psychother. 2011;18(1):75–79. doi: 10.1002/cpp.693.
    1. Zanarini M, Skodol A, Bender D, Dolan R, Sanislow C, Schaefer E, Morey L, Grilo C, Shea M, McGlashan T. et al.The Collaborative Longitudinal Personality Disorders Study: reliability of axis I and II diagnoses. J Pers Disord. 2000;14(4):291–299. doi: 10.1521/pedi.2000.14.4.291.
    1. Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): Psychometric properties. Psychol Med. 1996;26(3):477–486. doi: 10.1017/S0033291700035558.
    1. Trivedi MH, Rush AJ, Ibrahim HM, Carmody TJ, Biggs MM, Suppes T, Crismon ML, Shores-Wilson K, Toprac MG, Dennehy EB. et al.The Inventory of Depressive Symptomatology, Clinician Rating (IDS-C) and Self-Report (IDS-SR), and the Quick Inventory of Depressive Symptomatology, Clinician Rating (QIDS-C) and Self-Report (QIDS-SR) in public sector patients with mood disorders: a psychometric evaluation. Psychol Med. 2004;34(1):73–82. doi: 10.1017/S0033291703001107.
    1. The WHOQOL Group. Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med. 1998;28(3):551–558.
    1. Costa PT, McCrae RR. Revised NEO Personality Inventory (NEO-PI-R) and the Five Factor Inventory (NEO-FFI): Professional Manual. Odessa, Florida: Psychological Assessment Resources Inc; 1992.
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74. doi: 10.1097/00005650-198601000-00007.
    1. Treynor W, Gonzalez R, Nolen-Hoeksema S. Rumination reconsidered: A psychometric analysis. Cognitive Therapy and Research. 2003;27:247–259. doi: 10.1023/A:1023910315561.
    1. Van der Does W. Cognitive reactivity to sad mood: structure and validity of a new measure. Behav Res Ther. 2002;40(1):105–120. doi: 10.1016/S0005-7967(00)00111-X.
    1. Baer RA, Smith GT, Hopkins J, Krietemeyer J, Toney L. Using self-report assessment methods to explore facets of mindfulness. Assessment. 2006;13(1):27–45. doi: 10.1177/1073191105283504.
    1. Neff KD. Development and validation of a scale to measure self-compassion. Self and Identity. 2003;2:223–250. doi: 10.1080/15298860309027.
    1. Brown KW, Ryan RM. The benefits of being present: Mindfulness and its role in psychological well-being. J Pers Soc Psychol. 2003;84:822–848.
    1. Thompson ER. Development and validation of an internationally reliable short-form of the positive and negative affect schedule (PANAS) Journal of Cross-Cultural Psychology. 2007;38(2):227–242. doi: 10.1177/0022022106297301.
    1. Beecham J, Knapp M. In: Measuring Mental Health Needs. Thornicroft Brewin C, Wing JK, editor. London: Gaskell; 1992. Costing psychiatric interventions.
    1. Oostenbrink JB, Bouwmans CAM, Koopmanschap MA, Rutten FFH. Handleiding voor kostenonderzoek. Methoden en standaard kostprijzen voor economische evaluaties in de gezondheidszorg. Geactualiseerde versie. Diemen: College voor zorgverzekeringen; 2004. p. 2004.
    1. Koopmanschap MA, Rutten FF, van Ineveld BM, van Roijen L. The friction cost method for measuring indirect costs of disease. J Health Econ. 1995;14(2):171–189. doi: 10.1016/0167-6296(94)00044-5.
    1. The EuroQol Group. EuroQol-a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199–208.
    1. Hardeveld F, Spijker J, De Graaf R, Nolen WA, Beekman AT. Prevalence and predictors of recurrence of major depressive disorder in the adult population. Acta Psychiatr Scand. 2010;122(3):184–191.
    1. Bockting CL, Schene AH, Spinhoven P, Koeter MW, Wouters LF, Huyser J, Kamphuis JH. Preventing relapse/recurrence in recurrent depression with cognitive therapy: a randomized controlled trial. J Consult Clin Psychol. 2005;73(4):647–657.
    1. Preacher KJ, Hayes AF. Asymptotic and resampling strategies for assessing and comparing indirect effects in multiple mediator models. Behav Res Methods. 2008;40(3):879–891. doi: 10.3758/BRM.40.3.879.
    1. Kenny DA, Korchmaros JD, Bolger N. Lower level mediation in multilevel models. Psychol Methods. 2003;8(2):115–128.

Source: PubMed

Patrocinadores y Colaboradores

Condiciones médicas

Intervenciones de drogas

3
Suscribir